Genmab starts HuMax-CD4 Phase II

Genmab (CSE:GEN) began an international Phase II trial of HuMax-CD4 in about 20 patients with refractory or relapsed non-cutaneous T cell lymphoma. Patients will receive HuMax-CD4 once weekly for 12 w...